JP2024150445A5 - - Google Patents

Download PDF

Info

Publication number
JP2024150445A5
JP2024150445A5 JP2024099523A JP2024099523A JP2024150445A5 JP 2024150445 A5 JP2024150445 A5 JP 2024150445A5 JP 2024099523 A JP2024099523 A JP 2024099523A JP 2024099523 A JP2024099523 A JP 2024099523A JP 2024150445 A5 JP2024150445 A5 JP 2024150445A5
Authority
JP
Japan
Prior art keywords
antigen
binding protein
seq
pharmaceutical composition
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024099523A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024150445A (ja
Filing date
Publication date
Priority claimed from JP2020515692A external-priority patent/JP7599332B2/ja
Application filed filed Critical
Publication of JP2024150445A publication Critical patent/JP2024150445A/ja
Publication of JP2024150445A5 publication Critical patent/JP2024150445A5/ja
Pending legal-status Critical Current

Links

JP2024099523A 2017-09-18 2024-06-20 クローディン６抗体及びがんを治療するための方法 Pending JP2024150445A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762560143P 2017-09-18 2017-09-18
US62/560,143 2017-09-18
JP2020515692A JP7599332B2 (ja) 2017-09-18 2018-09-18 クローディン６抗体及びがんを治療するための方法
PCT/US2018/051610 WO2019056023A2 (en) 2017-09-18 2018-09-18 ANTIBODIES AGAINST CLAUDIN 6 AND METHODS OF TREATING CANCER

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020515692A Division JP7599332B2 (ja) 2017-09-18 2018-09-18 クローディン６抗体及びがんを治療するための方法

Publications (2)

Publication Number Publication Date
JP2024150445A JP2024150445A (ja) 2024-10-23
JP2024150445A5 true JP2024150445A5 (enExample) 2026-02-06

Family

ID=65723110

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020515692A Active JP7599332B2 (ja) 2017-09-18 2018-09-18 クローディン６抗体及びがんを治療するための方法
JP2024099523A Pending JP2024150445A (ja) 2017-09-18 2024-06-20 クローディン６抗体及びがんを治療するための方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020515692A Active JP7599332B2 (ja) 2017-09-18 2018-09-18 クローディン６抗体及びがんを治療するための方法

Country Status (22)

Country Link
US (4) US20200291111A1 (enExample)
EP (2) EP3826667B1 (enExample)
JP (2) JP7599332B2 (enExample)
KR (2) KR20250050137A (enExample)
CN (2) CN111565744B (enExample)
AU (2) AU2018334434B2 (enExample)
BR (1) BR112020005196A2 (enExample)
CA (1) CA3076207A1 (enExample)
CZ (1) CZ2021138A3 (enExample)
DK (1) DK3826667T3 (enExample)
ES (1) ES2986343T3 (enExample)
FI (1) FI3826667T3 (enExample)
GB (1) GB202103867D0 (enExample)
HU (1) HUE067603T2 (enExample)
IL (2) IL273196B2 (enExample)
MX (2) MX2020002921A (enExample)
NO (1) NO20210351A1 (enExample)
PL (1) PL3826667T3 (enExample)
PT (1) PT3826667T (enExample)
SG (1) SG11202002114RA (enExample)
SI (1) SI3826667T1 (enExample)
WO (1) WO2019056023A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3826667T1 (sl) * 2017-09-18 2024-09-30 The Regents Of The University Of California Protitelesa Claudin6 in metode zdravljenja raka
SG11202001430SA (en) 2017-09-29 2020-04-29 Daiichi Sankyo Co Ltd Antibody-pyrrolobenzodiazepine derivative conjugate
KR102063341B1 (ko) * 2018-12-31 2020-01-07 다이노나(주) Icam-1에 특이적으로 결합하는 항체 및 그의 용도
MA54955A (fr) 2019-02-15 2021-12-22 Integral Molecular Inc Anticorps anti-claudine 6 et leurs utilisations
WO2020191344A1 (en) * 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 bispecific antibodies
SG11202109986TA (en) * 2019-03-20 2021-10-28 Univ California Claudin-6 antibodies and drug conjugates
CN115956089A (zh) 2020-05-04 2023-04-11 加利福尼亚大学董事会 抑制性抗enpp1抗体
CN112386687B (zh) * 2020-12-09 2021-05-04 爱龄医美国际健康咨询服务(北京)有限公司 一种干细胞外泌体及其在药品和化妆品中的应用
US20250042996A1 (en) * 2021-11-16 2025-02-06 Christopher Bebbington Antibodies to anti-siglec-9 and multispecific antibodies targeting siglec-7 and siglec-9
KR20240153421A (ko) * 2022-02-09 2024-10-22 세라 프로그노스틱스 인코포레이티드 Shbg 및 ibp4 항체 및 이를 사용하는 방법
EP4626933A1 (en) 2022-11-30 2025-10-08 Integral Molecular, Inc. Antibodies directed to claudin 6, including bispecific formats thereof
CN121793985A (zh) 2023-05-25 2026-04-03 加利福尼亚大学校董会 治疗癌症的方法
WO2025075127A1 (ja) * 2023-10-04 2025-04-10 公立大学法人福島県立医科大学 がんのバイオマーカー及び抗体治療
WO2025146161A1 (en) * 2024-01-04 2025-07-10 Hansoh Bio Llc Antibody, antigen-binding fragment and medical use thereof
WO2025162270A1 (zh) * 2024-02-01 2025-08-07 江苏恒瑞医药股份有限公司 抗cldn6抗体、其抗体-药物偶联物及其医药用途
WO2026084392A1 (ko) * 2024-10-14 2026-04-23 에이비엘바이오 주식회사 항-클라우딘6 항체 및 이의 용도

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
DE3587500T2 (de) 1984-12-04 1993-12-16 Lilly Co Eli Tumorbehandlung bei Säugetieren.
AU2546399A (en) 1998-02-10 1999-08-30 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
EP1126871A2 (en) 1998-10-16 2001-08-29 The Government of The United States of America, as represented by The Department of Health and Human Services Combination therapy with vip antagonist
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
EP1257289A1 (en) 2000-02-08 2002-11-20 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
DE60226641D1 (de) 2001-12-03 2008-06-26 Amgen Fremont Inc Antikörperkategorisierung auf der grundlage von bindungseigenschaften
EP1551505B1 (en) 2002-10-04 2010-02-24 Microchips, Inc. Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
CA2672581A1 (en) * 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
EP2139458A4 (en) 2007-04-19 2013-01-23 Dong A Pharm Co Ltd BIODEGRADABLE MICRO BEADS COMPOSITION FOR CONTROLLED RELEASE OF GLUCOSE-CONTROLLED PEPTIDE AND FORMULATION THEREOF
US9274119B2 (en) * 2008-01-11 2016-03-01 The University Of Tokyo Anti-CLDN6 antibody
EP2404936A1 (en) * 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
RS58087B1 (sr) * 2011-05-13 2019-02-28 Ganymed Pharmaceuticals Gmbh Antitela za lečenje kancera koji eksprimira klaudin 6
WO2015014376A1 (en) * 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
BR112016010169A2 (pt) * 2013-11-06 2017-12-05 Stemcentrx Inc anticorpos anticlaudina e métodos de uso
SI3708579T1 (sl) * 2014-04-01 2024-09-30 Biontech Cell & Gene Therapies Gmbh Klavdin-6 specifični imunoreceptorji in T celični epitopi
SI3826667T1 (sl) * 2017-09-18 2024-09-30 The Regents Of The University Of California Protitelesa Claudin6 in metode zdravljenja raka

Similar Documents

Publication Publication Date Title
JP2023051986A (ja) Ｃｄ４７に対するヒト化及びキメラモノクローナル抗体
JP7784511B2 (ja) 抗ネクチン－４抗体、それを含むコンジュゲート、及びその適用
CN109320612B (zh) 抗her2抗体及其缀合物
JP2003525061A5 (enExample)
CN107735093A (zh) Cd123抗体和其结合物
WO2023025243A1 (zh) 抗Nectin-4抗体、药物缀合物及其制备方法和用途
JP2024501894A5 (enExample)
CN111655290A (zh) 抗组织因子抗体-药物偶联物及其在癌症治疗中的应用
JP2023516195A (ja) Ｃ１９ ｃ３８二特異性抗体
JP2024537323A5 (enExample)
JP2023536631A5 (enExample)
WO2024163630A2 (en) Anti-cdh17 antibodies and use of the same
US11110179B2 (en) Combination of CD33 antibody drug conjugates with chemotherapeutic agents
US20180296691A1 (en) Anti-efna4 antibody-drug conjugates
WO2023065594A1 (zh) 抗cd47-cldn18.2双特异性抗体及其用途
CN112996540B (zh) 一种c-Met ADC在制备治疗c-Met激酶抑制剂耐药的疾病的药物中的用途
JP2022530063A (ja) 抗体製剤
US20250092152A1 (en) Humanized antibody capable of binding to heg1 protein
CN120077073A (zh) 用于治疗里希特氏综合征的针对cd3和cd20的双特异性抗体
CN120695174A (zh) 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用
JP2022535276A5 (enExample)
JP2023536630A5 (enExample)
TWI922217B (zh) 用於治療類風濕性關節炎的抗體及其用途
JP7815590B2 (ja) ビメンチンを発現する腫瘍を治療するためのキットおよび容器
CN120435319A (zh) 抗-avb6抗体和抗体-药物缀合物及其在癌症治疗中的用途